You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for New Drug Application (NDA): 216185


✉ Email this page to a colleague

« Back to Dashboard


NDA 216185 describes MOTPOLY XR, which is a drug marketed by Aucta and is included in one NDA. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the MOTPOLY XR profile page.

The generic ingredient in MOTPOLY XR is lacosamide. There are twenty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
Summary for 216185
Tradename:MOTPOLY XR
Applicant:Aucta
Ingredient:lacosamide
Patents:3
Pharmacology for NDA: 216185
Suppliers and Packaging for NDA: 216185
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MOTPOLY XR lacosamide CAPSULE, EXTENDED RELEASE;ORAL 216185 NDA Aucta Pharmaceuticals, Inc. 73289-0063 73289-0063-1 1 BLISTER PACK in 1 CARTON (73289-0063-1) / 14 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK
MOTPOLY XR lacosamide CAPSULE, EXTENDED RELEASE;ORAL 216185 NDA Aucta Pharmaceuticals, Inc. 73289-0063 73289-0063-2 60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE, PLASTIC (73289-0063-2)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength100MG
Approval Date:May 4, 2023TE:RLD:Yes
Patent:⤷  Sign UpPatent Expiration:Jun 5, 2040Product Flag?YSubstance Flag?Delist Request?
Patented Use:ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
Patent:⤷  Sign UpPatent Expiration:Jun 5, 2040Product Flag?YSubstance Flag?Delist Request?
Patented Use:TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG
Patent:⤷  Sign UpPatent Expiration:Jun 5, 2040Product Flag?YSubstance Flag?Delist Request?
Patented Use:ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.